Immunic, Inc.
IMUX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.04 | 0.10 | -0.05 |
| FCF Yield | -11.82% | -26.73% | -19.76% | -25.48% |
| EV / EBITDA | -5.32 | -1.41 | -3.82 | -2.17 |
| Quality | ||||
| ROIC | -244.64% | -77.62% | 756.27% | -131.89% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.79 | 0.92 | 0.85 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 18.01% | -12.93% | 4.98% | -10.13% |
| Safety | ||||
| Net Debt / EBITDA | 1.37 | 2.03 | 0.52 | 1.35 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -16,520.23 | -11,526.28 | -11,848.42 |